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OBJECTIVE—On the basis of the role of activin A in inﬂamma-
tion, atherogenesis, and glucose homeostasis, we investigated
whether activin A could be related to glucometabolic abnormal-
ities in patients with acute myocardial infarction (MI).
RESEARCH DESIGN AND METHODS—Activin A measure-
ment and oral glucose tolerance tests (OGTTs) were performed
in patients (n = 115) with acute MI, without previously known
diabetes, and repeated after 3 months. Release of activin A and
potential anti-inﬂammatory effects of activin A were measured in
human endothelial cells. Activin A effects on insulin secretion
and inﬂammation were tested in human pancreatic islet cells.
RESULTS—1) In patients with acute MI, serum levels of activin
A were signiﬁcantly higher in those with abnormal glucose regu-
lation (AGR) compared with those with normal glucose regula-
tion. Activin A levels were associated with the presence of AGR 3
months later (adjusted odds ratio 5.1 [95% CI 1.73–15.17], P =
0.003). 2) In endothelial cells, glucose enhanced the release of
activin A, whereas activin A attenuated the release of interleukin
(IL)-8 and enhanced the mRNA levels of the antioxidant metallo-
thionein. 3) In islet cells, activin A attenuated the suppressive
effect of inﬂammatory cytokines on insulin release, counteracted
the ability of these inﬂammatory cytokines to induce mRNA ex-
pression of IL-8, and induced the expression of transforming
growth factor-b.
CONCLUSIONS—We found a signiﬁcant association between
activin A and newly detected AGR in patients with acute MI. Our
in vitro ﬁndings suggest that this association represents a counter-
acting mechanism to protect against inﬂammation, hyperglyce-
mia, and oxidative stress. Diabetes 60:1544–1551, 2011
T
ype 2 diabetes is a chronic disease with rapidly
increasing prevalence, and patients with type 2
diabetes have an increased risk of developing
coronary artery disease (CAD) (1,2). The coex-
istence of type 2 diabetes and CAD is considerable, and
type 2 diabetes has been rated as an equivalent of CAD. In
contrast, many patients with established CAD have type 2
diabetes or its pre-states (3). Thus, a high prevalence of
impaired glucose tolerance (IGT) and unknown type 2
diabetes has been reported in patients with CAD with no
previous diagnosis of diabetes (4–6). Abnormal glucose
regulation (AGR) (impaired fasting glucose [IFG], IGT, or
type 2 diabetes) is approximately twice as common among
patients with myocardial infarction (MI) as in population-
based controls (7), and the presence of AGR is a strong risk
factor for new cardiovascular events after acute MI (3,8,9).
The association between cardiovascular disease and
hyperglycemia may be explained by an accumulation of
cardiovascular risk factors associated with the metabolic
syndrome in patients with AGR (10). It may, however, also
relate to mechanisms triggered by hyperglycemia and in-
sulin resistance leading to cardiovascular damage before
the onset of overt diabetes (7,11). Moreover, experimental
and clinical data have illuminated a role of inﬂammation in
atherogenesis, and it has been suggested that atheroscle-
rosis, type 2 diabetes, and the metabolic syndrome are
multifactorial diseases characterized by chronic inﬂamma-
tion (12). However, the reasons for the association between
AGR and atherosclerotic disorders are not fully understood.
Activin A, a member of the transforming growth factor
(TGF)-b superfamily (13), has been recognized as a multi-
functional cytokine with roles in regulation of wound re-
pair, cell differentiation, and inﬂammation, and growing
evidence implicates a role for activin A in inﬂammatory
disorders potentially mediating both inﬂammatory and anti-
inﬂammatory effects (14). Activin A also has been sug-
gested to be important for glucose homeostasis, at least
partly through direct stimulatory effects on pancreatic b-cells
(15). However, reports on activin A levels in patients with
type 2 diabetes are few and include a small number of
patients (16,17). Furthermore, there are only a few reports on
activin A levels during acute coronary syndrome (ACS) and
no reports on patients with ST-elevation MI (STEMI) exclu-
sively. Moreover, no data exist on the association between
activin A and AGR in patients with CAD.
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ORIGINAL ARTICLEOn the basis of the role of activin A in inﬂammation,
atherogenesis, and glucose homeostasis, we investigated
whether activin A could be related to glucose abnormali-
ties associated with STEMI, potentially representing a
counteracting mechanism in response to AGR. This hy-
pothesis was investigated by different approaches, in-
cluding studies in a well-characterized population with
STEMI and experimental studies in endothelial cells and
pancreatic b-cells.
RESEARCH DESIGN AND METHODS
Study population. A total of 115 patients with a primary percutaneous cor-
onary intervention (PCI)-treated STEMI, originally included in a prospective
observational cohort study on the prevalence of AGR classiﬁed by an oral
glucose tolerance test (OGTT) (5), were investigated for a possible association
between circulating levels of activin A and AGR. In brief, patients with a pri-
mary PCI-treated STEMI were included if they were stable, without chest pain
or nausea, and aged ,85 years. Patients with previously known type 2 di-
abetes, persistent hyperglycemia (admission plasma glucose .11 mmol/L and
a fasting capillary glucose level .8 mmol/L), or renal failure (creatinine .200
mmol/L) were excluded. Only 17 patients had increased creatinine levels (.90
mmol/L). Seven patients had comorbidity that could potentially inﬂuence
activin A levels: cancer (n = 1), polymyalgia rheumatica (n = 2), vasculitis (n =
1), rheumatoid arthritis (n = 1), and arthritis urica (n = 2).
The patients in this substudy were randomly selected from the total study
population, and the baseline parameters (Table 1) did not differ from those of
the total population. All patients met at a 3-month follow-up, which included
a clinical examination, additional fasting blood sampling, and a repeated
OGTT. Activin A was measured in blood samples collected the ﬁrst morning
after a primary PCI-treated STEMI and at 3 months. For activin A analyses,
venous blood was drawn into pyrogen-free blood collection tubes without any
anticoagulant, and serum was allowed to clot before centrifugation (2,500g for
10 min). All samples were stored at 280°C and thawed only once. In addition,
blood samples for activin A analyses were collected in 45 of the patients be-
fore and 2 h after a standardized OGTT at the 3-month visit. For comparison,
activin A levels also were measured in 72 patients with stable CAD (61 [53, 69]
years of age, 61 male [85%]). The diagnosis of CAD was conﬁrmed in these
patients by coronary angiography showing at least 1-vessel disease.
The regional ethics committee approved the study. All patients provided
written and oral informed consent.
Deﬁnition of STEMI. STEMI was deﬁned as the typical increase and decrease
of troponin T with at least one value above the 99th percentile of the upper
reference limit in patients with symptoms of ischemia and new ST-elevation at
the J-point in two contiguous leads with the cutoff points of 0.2 mV in men or
0.15 mV in women in leads V2–V3 or 0.1 mV in other leads or new left bundle
branch block (18).
OGTT. A standardized 75 g OGTT (plasma glucose measurements at 0 and 120
min) was performed after an overnight fast (19). The patients were classiﬁed
glucometabolically according to the World Health Organization guidelines (20)
into one of the following categories (glucose in millimoles/liter): 1) normal
glucose tolerance, i.e., OGTT ,6.1 (baseline) and ,7.8 (2 h); 2) IFG, i.e.,
OGTT $6.1 ,7.0 (baseline) and ,7.8 (2 h); 3) IGT, i.e., OGTT ,7.0 (baseline)
and $7.8 ,11.1 (2 h); 4) type 2 diabetes, i.e., OGTT $7.0 (baseline) or OGTT
$11.1 (2 h). Patients with AGR were deﬁned as the sum of patients with IFG,
IGT, and type 2 diabetes (7).
Routine laboratory methods. Routine analyses, including plasma glucose
and HbA1c, were analyzed by use of conventional methods. Serum levels of
cardiac-speciﬁc troponin T (cTnT) were measured by electrochemiluminescence
technology for quantitative measurement (third-generation cTnT, Elecsys 2010;
Roche Diagnostics GmbH, Mannheim, Germany). The lower detection limit of
the assay is 0.01 mg/L, with a recommended diagnostic threshold of 0.03 mg/L.
Insulin was measured by a competitive radioimmunoassay (Linco Research, Inc.,
St. Charles, MO). C-peptide was determined by Immulite 2000 (Diagnostic Prod-
uct Corporation, Los Angeles, CA). Proinsulin and C-reactive protein (CRP) were
measured by enzyme immunoassays (EIAs) from DRG Instruments (Mar-
burg, Germany).
EIA. Serum levels of activin A were measured by a precoated EIA (R&D
Systems, Minneapolis, MI), whereas activin A in human umbilical vein
endothelial cell (HUVEC) supernatants was measured by EIA using matched
antibodies (R&D Systems) after activation with 3M Urea provided by the
manufacturer (St. Paul, MN). Interleukin (IL)-8 was measured by EIA from
R&D Systems. The inter- and intra-assay coefﬁcients of variation were ,10%
for all EIAs.
Endothelial cell culture. HUVECs were obtained from umbilical cord veins
by digestion with 0.1% collagenase A (Boehringer Mannheim, Mannheim,
Germany) and cultured as described previously (21). HUVECs were stimulated
with different concentrations of recombinant human activin A (R&D Systems),
recombinant human IL-1b (5 ng/mL, R&D Systems), or a combination thereof.
In a separate set of experiment, HUVECs were cultured in different concen-
trations of glucose, insulin (Sigma-Aldrich, St. Louis, MO), or a combination
thereof in a glucose-free Dulbecco’s modiﬁed Eagle’s medium containing
glucogenic and ketogenic amino acids (Life Technologies, Invitrogen, Carlsbad,
CA). At different time points, cell pellets and cell-free supernatants were col-
lected and stored at 280°C. In all experiments, the vehicle of the stimulus was
added as control.
Human islet isolation and culture. Following obtained consent from the
organ donor registry or relatives, pancreata from deceased donors were
transported from the donor hospital to the laboratory for islet isolation in
Uppsala, Sweden. Islets were isolated according to the automated method,
reﬁned by the Nordic Network for Islet Transplantation (22). Within 2–5 days
from isolation, aliquots of puriﬁed islet preparations were stimulated with
activin A (100 ng/mL; R&D Systems), a mixture of inﬂammatory cytokines
(IL-1b [10 ng/mL], interferon-g [IFN-g, 50 ng/mL], and tumor necrosis factor-a
[TNF-a, 10 ng/mL]; all from R&D Systems), or a combination thereof for 24 h
in CMRL-1066 media (ICN Biomedicals, Costa Mesa, CA) with 10% ABO-
identical serum. Cell pellets and supernatants were harvested and stored at
280°C until further analyses.
Glucose-stimulated insulin secretion in human islet cells. For static in-
sulin secretion in response to a glucose challenger, 20 islets were handpicked,
transferred into 24-transwell trays (Costar, Cambridge, MA), and preincubated
in 1.67 mmol/L glucose at 37°C (5% CO2) for 30 min. Thereafter, the islets were
incubated for 1 h in 1.67 mmol/L glucose (basal), before additional incubation
for 1 h in 20.0 mmol/L glucose (stimulated). Secreted insulin in the media was
measured by EIA (Mercodia AB, Uppsala, Sweden). The capacity for insulin
release was expressed as insulin stimulation index, calculated as the ratio of
stimulated to basal insulin secretion.
Real-time quantitative RT-PCR. Total RNA was extracted byMagNa Pure LC
RNA isolation kit III (Roche Diagnostics GmbH) and stored at 280°C. Primers
for metallothionein, IL-1b, IL-8/CXCL8, monocyte chemoattractant protein-1/
CCL2, and TGF-b were designed using the Primer Express software, version 2.0
(Applied Biosystems, Foster City, CA). Primer sequences could be provided by
request. Quantiﬁcation of mRNA was performed using the ABI Prism 7500
(Applied Biosystems). Gene expression of the housekeeping gene b-actin and
glyceraldehyde-3-phosphate dehydrogenase (Applied Biosystems) was used for
normalization.
TABLE 1
Baseline characteristics of 115 patients with an acute PCI-treated
STEMI
Patients
Age (years) 59 (52, 68)
Male, n (%) 97 (84)
Previous disorder:
MI, n (%) 5 (4.3)
Angina pectoris, n (%) 3 (2.6)
Hypertension (treated), n (%) 23 (20.0)
Hyperlipidemia (treated), n (%) 9 (7.8)
Status at baseline:
Current smoker, n (%) 49 (42.6)
cTnTmax (mg/L) 5.0 (2.5, 9.7)
BMI (kg/m2) 26 (24.3, 28.6)
Waist circumference (cm) 99 (94, 106)
Stent in culprit lesion, n (%) 109 (94.8)
Gp IIb/IIIa inhibitor-treated, n (%) 39 (33.9)
Single-coronary vessel disease, n (%) 73 (63.5)
Double-coronary vessel disease, n (%) 34 (29.6)
Triple-coronary vessel disease, n (%) 8 (7.0)
Time from symptoms to balloon (min) 239 (155, 370)
Medication at admission:
Aspirin 10 (8.7)
b-Blockers 11 (9.6)
Lipid-lowering agents 7 (6.1)
ACE inhibitors 3 (2.6)
Angiotensin II receptor blockers 11 (9.6)
Data are presented as median values (25th, 75th percentiles) or pro-
portions (%). cTnTmax, cTnT maximum; Gp, glycoprotein.
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75th percentiles or mean 6 SEM as appropriate. Categoric variables are
presented as proportions if not otherwise stated. Nonparametric statistics
were used throughout. Differences among groups were analyzed by Mann–
Whitney test for continuous variables. The Mantel–Haenszel method was used
to highlight potential effect modiﬁcation by the Breslow–Day test of
heterogeneity and to quantify potential confounders (23). Continuous varia-
bles were categorized into quartiles, and the variables were dichotomized into
high and low levels. A x
2 for trend across the quartiles of a variable identiﬁed
the cutoff point used. A logistic regression model, including a backward
elimination procedure, was performed to adjust for potential confounders.
Potential confounders (i.e., gender, age, current smoking, treated hyperten-
sion, treated hyperlipidemia, previous MI, multivessel disease, prior medica-
tion, time from symptoms to balloon, cTnT maximum, CRP, creatinine, BMI,
cholesterol, and triglycerides) that were associated with activin A levels or
AGR with a P , 0.2 were included in the model. P , 0.05 was considered
statistically signiﬁcant.
RESULTS
Study population. Baseline characteristics of the study
population are shown in Table 1. The patients were rela-
tively young, very few had a previous diagnosis of CAD,
and a majority of the patients had single-vessel disease.
The prevalence of AGR classiﬁed by an OGTT in-hospital
and 3 months later was 44 and 23%, respectively.
Association between circulating activin A and clinical
and glucometabolic variables. Serum levels of activin A
measured acutely, within a median time of 16.5 h of a pri-
mary PCI-treated STEMI (n = 115), were 0.23 (0.17, 0.29) ng/
mL, which increased after 3 months, comparable to activin A
levels in a group of patients with stable CAD (n = 72) (Fig. 1).
FIG. 1. Circulating activin A in patients with STEMI. Serum levels of
activin A measured in patients with STEMI (n = 115) the ﬁrst morning
after primary PCI and in a stable phase after 3 months. Serum levels of
activin A from patients (n = 72) with stable CAD are shown for com-
parison. Data are mean 6 SEM.
TABLE 2
Clinical and biochemical variables in patients with acute STEMI related to circulating activin A
Variables
Activin A
(,0.23 ng/mL)
Activin A
($0.23 ng/mL) P value
Measured in-hospital
Age (years) 54 (50, 63) 62 (56, 73) 0.6
Male, n (%) 49 (86.0) 48 (82.8) 0.0001
Hypertension (treated), n (%) 7 (12.3) 16 (27.6) 0.04
Statin treatment, n (%) 7 (12.3) 0 (0) 0.06
Aspirin treatment, n (%) 3 (30) 7 (70) 0.2
ACE inhibitor/ARB treatment, n (%) 4 (29) 10 (72) 0.08
Current smoker, n (%) 26 (45.6) 23 (39.7) 0.5
BMI (kg/m
2) 26 (24.3, 28.7) 26 (24.3, 27.8) 0.96
Comorbidity, n (%)* 1 (1.8) 6 (10.3) 0.06
cTnTmax (mg/L) 4.7 (2.1, 8.2) 6.9 (3.3, 10.8) 0.10
Cholesterol (mmol/L) 5.2 (4.4, 6.0) 5.2 (4.7, 5.8) 0.7
Triglycerides (mmol/L) 1.3 (1.0, 1.7) 1.2 (0.9, 1.8) 0.5
CRP (mg/L) 10.7 (4.4, 27.3) 17.7 (7.8, 47.6) 0.047
Creatinine (mmol/L
21) 70 (60, 82) 77 (66, 90) 0.06
Admission glucose (mmol/L) 6.5 (5.7, 7.7) 6.9 (6.4, 8.1) 0.035
Fasting glucose (mmol/L) 5.1 (4.8, 5.5) 5.5 (5.0, 6.3) 0.009
Two-hour glucose (mmol/L) 6.4 (5.6, 7.8) 7.6 (6.5, 8.9) 0.004
HbA1c (%) 5.4 (5.2, 5.5) 5.6 (5.4, 5.8) 0.0003
Insulin (pM) 69 (50, 86) 75 (51, 110) 0.3
C-peptide (pM) 788 (622, 1,029) 1,034 (746, 1,212) 0.01
Proinsulin (pM) 7.3 (5.0, 9.3) 9.5 (5.8, 14.1) 0.051
IL-8 (pg/mL) 14.9 (13.7, 17.1) 15.3 (12.6, 18.3) 0.84
Measured at 3 months
Fasting glucose (mmol/L) 4.9 (4.6, 5.4) 5.2 (4.9, 5.6) 0.007
Two-hour glucose (mmol/L) 5.4 (4.4, 6.6) 5.7 (4.8, 7.8) 0.16
HbA1c (%) 5.5 (5.3, 5.7) 5.6 (5.4, 5.9) 0.007
Insulin (pM) 68 (46, 86) 72 (53, 98) 0.3
C-peptide (pM) 781 (603, 992) 853 (685, 1,192) 0.052
Proinsulin (pM) 6.3 (4.6, 8.1) 6.3 (4.8, 10.2) 0.5
CRP (mg/L) 2.02 (0.79, 2.96) 3.27 (1.58, 5.88) 0.02
BMI (kg/m
2) 26.1 (24.4, 28.7) 26.2 (23.8, 28.4) 0.6
Current smoker, n (%) 14 (24.6) 7 (12.1) 0.08
Cholesterol (mmol/L) 4.2 (4.0, 4.6) 4.0 (3.6, 4.6) 0.06
Triglycerides (mmol/L) 1.2 (0.9, 1.5) 1.2 (0.9, 1.5) 0.7
Data are presented as median values (25th, 75th percentiles) or proportions. Clinical and biochemical variables in patients with acute STEMI
related to high or low activin A concentrations measured within 24 h after an acute PCI (median value as cutoff point). ARB, angiotensin II
receptor; cTnTmax, cTnT maximum. *One patient with cancer and six patients with inﬂammatory diseases.
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at baseline were older, were more likely to have hyper-
tension, had higher CRP and creatinine levels, and were
more unlikely to use statins (Table 2).
Moreover, patients with high activin A levels had sig-
niﬁcantly more glucometabolic abnormalities (Table 2).
Thus, patients with high activin A levels at baseline had
higher glucose levels at admission, higher levels of glucose
during the OGTT, and higher levels of HbA1c and C-peptide
in-hospital. After 3 months, these patients had higher
fasting glucose levels and higher HbA1c compared with
those with low activin A levels (Table 2). In line with this,
serum levels of activin A measured in-hospital were sig-
niﬁcantly higher in patients with abnormal compared with
normal glucose regulation, both when classiﬁed by an
OGTT in-hospital and after 3 months (Table 3). In addition,
activin A levels measured after 3 months remained higher,
although only borderline statistically signiﬁcant, in the
patients classiﬁed into AGR on the basis of the OGTT
performed at the same time point (Table 3).
High levels of activin A at baseline are associated
with AGR after 3 months. Activin A measured in-hospital
was strongly associated with the presence of AGR classi-
ﬁed by an OGTT at 3 months (Table 3). Thus, trend anal-
ysis for the presence of AGR across quartiles of activin A
demonstrated a signiﬁcant trend for the odds ratio (OR) of
having AGR at 3 months with increasing activin A con-
centrations (P = 0.012), identifying a threshold of activin A
at the median value ($0.23 ng/mL, Fig. 2). In univariate
analyses, high levels of activin A ($0.23 ng/mL) measured
in-hospital were associated with AGR classiﬁed 3 months
after the acute STEMI with an OR of 5.9 (95% CI 2.04–
17.10; P = 0.004). Activin A remained associated with AGR
after adjustment for potential confounders, including cre-
atinine levels and use of prior medication (see RESEARCH
DESIGN AND METHODS), with an OR of 5.1 (95% CI 1.73–15.17,
P = 0.003).
Patients with comorbidity (n = 7) (i.e., autoimmune
diseases or cancer, Table 2) had signiﬁcantly higher activin
A levels at baseline (data not shown), but notably, the
signiﬁcant association between activin A at baseline and
the presence of AGR at 3 months was still present when
patients with comorbidity were excluded (n = 108, OR 8.1
[95% CI 2.5–25.9], P , 0.0001).
High activin A levels are associated with high levels of
glucose parameters during OGTT. In 45 patients, activin
A levels were measured during OGTT at the 3-month follow-
up. When the patients were classiﬁed according to activin
A levels measured 2 h after oral glucose loading (above or
below the 75th percentile, 0.302 ng/mL), those with high
activin A levels had signiﬁcantly higher levels of glucose,
insulin, and C-peptide at the same time point than the
other patients (Fig. 3).
Glucose induces activin A release in endothelial cells.
The endothelium is a crucial target in both atherosclerosis
and diabetes and an important cellular source of activin A.
Therefore, to further elucidate the association between
AGR and activin A, we examined the ability of glucose and
insulin to promote activin A release in endothelial cells.
When HUVECs were exposed to glucose, there was a dose-
dependent increase in activin A release (Fig. 4A). The
combined effect of insulin was more complex. Although
insulin showed an enhancing effect on the glucose-stimulated
activin A release at a concentration of 5 nmol/L, compa-
rable to the insulin concentration seen during OGTT in
those with high activin A levels, a biphasic pattern was
seen at higher and potentially supraphysiologic insulin
concentration (25 nmol/L), with enhancing effects at low
TABLE 3
Activin A levels related to glucometabolic state in patients with
STEMI
NGR AGR
(in-hospital) (in-hospital)
(N = 64) (N = 51) P value
Activin A
(ng/mL)
(in-hospital) 0.212 (0.169, 0.261) 0.251 (0.182, 0.339) 0.023
NGR AGR
(at 3 months) (at 3 months)
(N = 89) (N = 26) P value
Activin A
(ng/mL)
(in-hospital) 0.213 (0.168, 0.273) 0.261 (0.239, 0.334) 0.009
Activin A
(ng/mL)
(at 3 months) 0.290 (0.237, 0.367) 0.366 (0.286, 0.464) 0.052
Data are presented as median values (25th, 75th percentiles). Activin
A measured in-hospital and at 3 months (in patients with STEMI)
according to glucometabolic classiﬁcation by an OGTT in-hospital
and at 3 months. NGR, normal glucose regulation.
FIG. 3. Association between activin A levels and glucometabolic pa-
rameters during an OGTT. An OGTT was performed in stable patients
(n = 46) 3 months after an acute STEMI. Glucose (A), insulin (B), and
C-peptide (C) levels, measured 2 hours after glucose loading, in patients
with high (‡75th percentile, 0.302 ng/mL) and low (<75th percentile)
activin A measured at the same time point. Data are mean 6 SEM.
FIG. 2. Association between activin A and AGR. Activin A was measured
in-hospital in patients with acute STEMI, classiﬁed 3 months later by an
OGTT into AGR and normal glucose regulation. ORs of having AGR by
quartiles of activin A are shown (P for trend; P = 0.012). The median
value (arrow) was used as the cutoff for dichotomizing activin A into
high and low levels.
G.Ø. ANDERSEN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1547glucose concentrations and suppressive effects at high
glucose concentrations.
Anti-inﬂammatory and antioxidative effects of activin
A in endothelial cells. On the basis of our previous ﬁnd-
ings with anti-inﬂammatory effects of activin A in peripheral
blood mononuclear cells from patients with CAD (24), we
next investigated whether activin A could have similar
effects in endothelial cells, potentially mediating pro-
tective responses during AGR. Indeed, activin A attenu-
ated the release of IL-8, a prototypical endothelial-derived
chemokine, in both unstimulated and IL-1b–stimulated
cells after culturing for 24 h (Fig. 4B). In contrast, activin
A enhanced the mRNA levels of metallothionein (Fig. 4C),
an antioxidant enzyme that has been found to be pro-
tective in relation to oxidative stress-induced damage in
diabetes (25).
Our in vitro ﬁndings may suggest an interaction between
activin A and IL-8, but we found no signiﬁcant correlations
in patients with STEMI, either acutely or at the 3-month
follow-up, between serum levels of IL-8 and activin A (data
not shown). However, a positive correlation between IL-8
and activin A measured 2 h after glucose loading at 3
months was observed (0.32, P = 0.03).
Effects of activin A in human pancreatic islet cells. To
further elucidate the effects of increased activin A levels in
relation to AGR in patients with PCI-treated STEMI, we
next examined the ability of activin A to modulate insulin
secretion and inﬂammation in human islet cells. In-
ﬂammation, and in particular IL-1b, has been implicated in
the pathogenesis of b-cell dysfunction in relation to type 2
diabetes (26). Therefore, the cells were also costimulated
with a combination of the inﬂammatory cytokines IL-1b,
TNF-a, and IFN-g. Although activin A had no signiﬁcant
effect on the capacity for insulin release (i.e., insulin
stimulation index) on its own, it totally abolished the
suppressive effect of the inﬂammatory cytokines on the
insulin stimulation index (Fig. 5A). Although activin A had
no effect on its own, it attenuated the enhancing effect of
the inﬂammatory cytokines on mRNA expression of IL-8
and IL-1b, but not of monocyte chemoattractant protein-1,
in pancreatic islet cells (Fig. 5B). Finally, although activin
A markedly increased mRNA levels of TGF-b on its own,
it did not counteract the suppressive effect of the in-
ﬂammatory “cocktail” on this anti-inﬂammatory cytokine
(Fig. 5B).
DISCUSSION
The high prevalence of AGR in patients with CAD and no
previous diagnosis of type 2 diabetes is an emerging prob-
lem in clinical medicine. The current study showed that
serum levels of activin A are associated with AGR in
patients with acute STEMI without known type 2 diabetes.
The association between high activin A levels and high
glucose levels was also seen during OGTT. Our in vitro
studies suggest that activin A may exert anti-inﬂammatory
and antioxidative effects in endothelium, as well as insulin-
stimulating and anti-inﬂammatory effects in human islet
cells. It is tempting to hypothesize that the increased activin
A levels in relation to AGR could represent a counteracting
mechanism to protect against hyperglycemia and hyper-
insulinemia and their consequences.
There are a few previous reports on activin A levels
during ACS showing increased, similar, or, as in the cur-
rent study, lower levels of activin A in patients with ACS
compared with stable CAD (24,27). The current study,
however, is the ﬁrst report on an association between se-
rum activin A levels and AGR in patients with STEMI
FIG. 4. Interaction between activin A and endothelial cells. A: The effect of various concentrations of glucose, insulin, or a combination thereof
on activin A levels in HUVEC supernatants after culturing for 48 h as assessed by EIA measurements. Data are mean 6 SEM (n = 4). *P < 0.05,
**P < 0.01, and ***P < 0.001 vs. no glucose (two left panels). *P < 0.05 and **P < 0.01 vs. no insulin. †P < 0.05 vs. 5 nmol/L insulin (right panel).
The effect of different concentrations of activin A on the spontaneous and IL-1b–stimulated (5 ng/mL) release of IL-8 (B) and the unstimulated
expression of metallothionein (C) after culturing for 24 and 4 h, respectively. IL-8 was measured by EIA, and metallothionein was assessed by RT-
PCR in relation to the control gene b-actin. Data are mean 6 SEM (n = 5). *P < 0.05 vs. unstimulated (or IL-1b–stimulated) cells. MT, metallo-
thionein.
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measured the 1st day after a PCI-treated STEMI, were
associated with a ﬁvefold increase in the odds of being
classiﬁed with AGR 3 months later. This association was
also present when adjusting for covariates. Moreover,
patients with high activin A levels during STEMI had
signiﬁcantly elevated levels of HbA1c and C-peptide in-
hospital, suggesting that the association between activin
A and glucometabolic disturbances also may have been
present before the acute MI.
The reason for the association between activin A levels
and AGR is at present not clear, but our ﬁndings may
suggest that glucose and insulin directly could induce
activin A release. During OGTT, performed at the 3-month
follow-up visit, there was a signiﬁcant association between
high activin A responses and high levels of glucose, insulin,
and C-peptide. In addition, in endothelial cells, being an
important cellular source of activin A (28), glucose in-
duced a signiﬁcant increase in activin A release. At an in-
sulin concentration comparable to that seen during OGTT,
insulin further enhanced activin A levels. Insulin has been
shown to induce activin A production in macrophages,
potentially contributing to the anti-inﬂammatory effects of
insulin during systemic inﬂammation (29). Our ﬁndings
suggest that the association between activin A levels and
AGR could reﬂect a direct stimulatory effect of glucose
and insulin on activin A release, at least partly involving
effects on endothelial cells.
Activin A has been shown to possess anti-inﬂammatory
properties under certain circumstances. Activin A is rap-
idly induced during systemic inﬂammation (30) and has
been found to antagonize IL-6–mediated effects within
hepatocytes (31), and we have previously shown anti-
inﬂammatory effects in preactivated peripheral blood
mononuclear cells from patients with CAD (24). The en-
dothelium is an important target for vascular complication
in atherosclerosis and type 2 diabetes (32), and the cur-
rent study showed that activin A attenuated the release of
the proatherogenic chemokine IL-8 from endothelial cells
and enhanced the expression of the antioxidative enzyme
metallothionein. Metallothionein may protect heart and
kidney against diabetes-induced pathophysiology (33) and
has been related to protection against cardiac endoplasmic
reticulum stress in diabetes (34). Although our ﬁndings
will have to be conﬁrmed in the in vivo situation, our data
suggest that activin A has the potential to attenuate vascular
inﬂammation and oxidative stress in disorders, such as ath-
erosclerosis and type 2 diabetes. The current study found
no correlation between activin A and IL-8 in serum. How-
ever, an interaction between activin A and IL-8 within the
endothelial microenvironment may not necessarily be reﬂected
in a correlation in serum levels, which reﬂect the contribution
from many organ systems. However, our ﬁnding of a positive
correlation between IL-8 and activin A during OGTT suggests
some interaction between activin A and IL-8 during hyper-
glycemia also in vivo.
Several studies have demonstrated a role for TGF-b
family cytokines in regulating pancreatic b-cell function
(35). Activin A has been shown to be expressed in human
pancreatic islets cells (36) and was found to act as an
autocrine factor enhancing insulin secretion in the pres-
ence of glucose in the same cell type (15). Our results
conﬁrmed the proposed enhancing effect of activin A on
insulin release and added new information to the possible
protecting effects of activin A on pancreatic islet cells.
Inﬂammation, in particular enhanced IL-1 activity, seems
to be important in the pathogenesis of type 2 diabetes at
least partly by inhibiting the function of pancreatic b-cells
(26). The current study showed that activin A 1) abolished
the suppressive effect of IL-1b, in combination with TNF-a
and IFN-g, on the insulin stimulation index; 2) attenuated
the inﬂammatory response of these inﬂammatory cytokines;
and 3) induced the expression of the anti-inﬂammatory
cytokine TGF-b in human pancreatic islet cells. TGF-b and
activin A share common signal transduction pathways in-
volving increased phosphorylation of Smads (35,37), and
TGF-b has been shown to protect pancreatic b-cell func-
tion in mice models (38). If similar effects may be seen of
activin A or if the anti-inﬂammatory effects of activin A are
mediated through TGF-b activation would need to be clar-
iﬁed. However, the inability of activin A to counteract the
suppressive effects of the inﬂammatory cytokines on TGF-b
levels suggests that the counteracting effects of activin A on
IL-8 and IL-1b expression in cytokine-exposed pancreatic
islet cells do not involve TGF-b.
Activin A is released during various inﬂammatory con-
dition, potentially as a counteracting mechanism (30). It is
possible that similar mechanisms could be operating as
FIG. 5. Effects of activin A in human pancreatic islet cells. The effect
of activin A (100 ng/mL), a mixture of inﬂammatory cytokines (IL-1b
[10 ng/mL], IFN-g [50 ng/mL], and TNF-a [10 ng/mL]), or a combination
thereof on the capacity for glucose-stimulated insulin release, ex-
pressed as insulin stimulation index (culture time 1 h after determi-
nation of basal insulin secretion, A), and on mRNA levels of IL-8, IL-1b,
monocyte chemoattractant protein-1, and TGF-b (culture time 24 h, B)
in human pancreatic islet cells. mRNA was assessed by RT-PCR in re-
lation to the control gene b-actin. Data are mean 6 SEM (n =4 –6). *P <
0.05 and ***P < 0.001 vs. inﬂammatory cytokines without activin A.
†P < 0.05 vs. control cells (vehicle). Act A, activin A; Ctr, control; Inﬂ,
inﬂammatory cytokines; MCP, monocyte chemoattractant protein.
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MI. Thus, activin A may be released as a consequence of
hyperglycemia and low-grade hyperinsulinemia as a coun-
teracting response to protect various compartments, such
as endothelium and pancreatic b-cells against inﬂammation
and oxidative stress, as well as other harmful consequences
of these glucometabolic disturbances. The current study
has certain limitations, such as a relatively low number of
patients. Because we lack data on activin A clearance, we
cannot exclude that the increased serum activin A levels, at
least in part, are due to reduced clearance and not in-
creased production of activin A. One might also argue that
the concentrations of activin A used in the in vitro experi-
ments (10 and 100 ng/mL) are not relevant to the in vivo
situation (serum levels ;0.3 ng/mL). However, activin A
concentrations in supernatants from endothelial cells that
were exposed to glucose and insulin were 2–2.5 ng/mL, and
it is not inconceivable that activin A concentrations may be
even higher in endothelial cells within an inﬂammatory
microenvironment, such as in patients with atherosclerotic
disorders.
The current study demonstrated an association between
circulating activin A and AGR in patients with acute
STEMI without previously known diabetes. Our ﬁndings
suggest that this association may reﬂect a direct inter-
action between insulin and glucose and activin A, poten-
tially representing a counteracting mechanism to protect
against inﬂammation and oxidative stress in these patients.
Further studies are needed to clarify whether activin A
could represent a therapeutic target in these overlapping
disorders (i.e., atherosclerosis and type 2 diabetes).
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